| University of Sydney | |
|---|---|
| Location | Sydney, New South Wales, Australia |
| Type | Public Research University |
| Founded | 1850 |
| Students | ~70,000 |
| Website | https://sydney.edu.au |
| Focus Areas | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Huntington's Disease, Dementia |
The University of Sydney (USYD) is Australia's first university, established in 1850. Located in Sydney, New South Wales, it is one of the world's leading research universities with particular strength in medicine, health sciences, and neuroscience[1]. The university enrolls approximately 70,000 students and employs over 8,000 academic staff, making it the largest university in Australia.
The university has been at the forefront of neurodegenerative disease research in the Asia-Pacific region. The Brain and Mind Centre brings together clinicians, researchers, and trainees to advance understanding and treatment of brain disorders including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
The University of Sydney was founded in 1850 as the first university in Australia and the Southern Hemisphere. The medical school was established in 1883, and neuroscience research programs expanded significantly from the 1970s onwards.
The Brain and Mind Centre was established in 2015 as a multidisciplinary hub for neuroscience research, consolidating previously distributed research programs. The Centre brings together researchers from neurology, psychiatry, neuroscience, and engineering to address complex brain disorders.
The University's Brain and Mind Centre is a multidisciplinary hub for neuroscience and neurological disease research[2]:
The university is a leading center for Parkinson's disease research:
Programs include:
The university is an international leader in ALS research:
| Disease Area | Research Focus | Key Researchers |
|---|---|---|
| Parkinson's Disease | Alpha-synuclein, LRRK2, gait analysis | Prof. Simon J. G. Lewis |
| Alzheimer's Disease | Biomarkers, neuroimaging, clinical trials | Prof. Karen L. M. S. |
| ALS | Genetic factors, biomarkers | Prof. Matthew C. Kiernan |
| Multiple Sclerosis | Neuroprotection, remyelination | Prof. Michael H. Barnett |
| Huntington's Disease | Genetic therapies, biomarker development | Prof. Clement J. L. Loy |
| Researcher | Position | Focus Areas | H-index |
|---|---|---|---|
| Prof. Simon J. G. Lewis | Parkinson's Research Lead | Movement disorders, gait analysis | 80 |
| Prof. Matthew C. Kiernan | ALS Program Director | Motor neuron disease, biomarkers | 100 |
| Prof. Michael H. Barnett | MS Research Lead | Neuroimmunology, demyelination | 70 |
| Prof. Ian P. Hickie | Brain and Mind Centre Director | Depression, neuropsychiatry | 75 |
The university provides clinical services through affiliated hospitals:
The University of Sydney offers extensive training in neuroscience and neurodegeneration:
USYD maintains active collaborations with:
Official Website. 2026. ↩︎
Lewis SJG, Shine JM. Parkinson's disease: biomarkers and treatment. Nature Reviews Neurology. 2020. ↩︎
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A. Amyotrophic lateral sclerosis. Lancet. 2021. ↩︎